Wearable Technology and Its Potential Role in Cardiovascular Health Monitoring and Disease Management

Background: Cardiovascular disease (CVD) remains the foremost cause of death globally, accounting for approximately 17.9 million deaths in 2019, 32% of all global fatalities with myocardial infarction and stroke constituting 85% of these. The disproportionate burden in low- and middle-income countries underscores the urgent need for scalable, technology-driven preventive and diagnostic strategies. Wearable technology represents a paradigm shift in cardiovascular health monitoring by facilitating continuous, real-time physiological assessment and early disease detection. Objectives: To critically synthesize and appraise the current evidence on wearable technology for cardiovascular disease prevention, early detection, and long-term management, emphasizing its clinical applications, integration with digital ecosystems, and implications for precision cardiology. Methods: A comprehensive, multi-database literature search was conducted spanning January 2000 to 2025. The electronic databases PubMed, Scopus, Web of Science, ScienceDirect, IEEE Xplore, and Cochrane Library, along with Google Scholar for gray literature, were systematically queried. Search terms combined MeSH and free-text keywords, including "wearable technology," "cardiovascular monitoring," "arrhythmia detection," "heart failure," "remote patient monitoring," "artificial intelligence," and "digital health." Study selection followed PRISMA-aligned screening principles, with inclusion criteria encompassing peer-reviewed clinical trials, systematic reviews, and technology validation studies focusing on cardiovascular applications of wearable devices. Exclusion criteria included nonhuman studies, non-English papers, and reports lacking clinical or technical relevance. Data extraction was independently performed by two reviewers, emphasizing device characteristics, monitoring parameters, diagnostic accuracy, patient outcomes, and integration with healthcare infrastructure. Methodological quality was appraised using standardized critical-appraisal tools. Supplementary evidence was retrieved from the World Health Organization, U.S. FDA, and European Medicines Agency to contextualize regulatory and translational perspectives. Results: Wearable devices demonstrated robust capability in continuous cardiovascular monitoring, enabling early detection of arrhythmias, hypertension, heart failure, and ischemic events. Devices integrating photoplethysmography, ECG, biosensors, and machine-learning algorithms significantly enhanced diagnostic sensitivity while improving patient engagement and lifestyle modification. Integration with telemedicine, artificial intelligence (AI), and the Internet of Medical Things (IoMT) enabled predictive analytics and personalized care. Major limitations included variability in data accuracy, interoperability barriers, regulatory heterogeneity, and privacy vulnerabilities. Nonetheless, aggregated evidence indicates substantial improvement in early detection, remote disease management, and patient outcomes. Conclusion: Wearable technology stands at the frontier of precision cardiovascular medicine, offering continuous, noninvasive, and data-driven insights into patient health. The convergence of AI, IoMT, and real-world data integration positions wearables as indispensable tools for risk stratification and remote management. Future work should prioritize standardized validation frameworks, cybersecurity reinforcement, and equitable global accessibility to maximize clinical impact and population-level benefits.